全文获取类型
收费全文 | 4013篇 |
免费 | 411篇 |
国内免费 | 102篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 147篇 |
妇产科学 | 53篇 |
基础医学 | 464篇 |
口腔科学 | 63篇 |
临床医学 | 544篇 |
内科学 | 857篇 |
皮肤病学 | 193篇 |
神经病学 | 255篇 |
特种医学 | 223篇 |
外科学 | 486篇 |
综合类 | 130篇 |
一般理论 | 2篇 |
预防医学 | 453篇 |
眼科学 | 36篇 |
药学 | 442篇 |
中国医学 | 3篇 |
肿瘤学 | 162篇 |
出版年
2021年 | 53篇 |
2020年 | 34篇 |
2019年 | 48篇 |
2018年 | 54篇 |
2017年 | 37篇 |
2016年 | 63篇 |
2015年 | 56篇 |
2014年 | 75篇 |
2013年 | 123篇 |
2012年 | 169篇 |
2011年 | 183篇 |
2010年 | 122篇 |
2009年 | 95篇 |
2008年 | 190篇 |
2007年 | 217篇 |
2006年 | 184篇 |
2005年 | 192篇 |
2004年 | 158篇 |
2003年 | 147篇 |
2002年 | 129篇 |
2001年 | 142篇 |
2000年 | 139篇 |
1999年 | 115篇 |
1998年 | 81篇 |
1997年 | 68篇 |
1996年 | 57篇 |
1995年 | 67篇 |
1994年 | 53篇 |
1993年 | 68篇 |
1992年 | 90篇 |
1991年 | 82篇 |
1990年 | 90篇 |
1989年 | 74篇 |
1988年 | 85篇 |
1987年 | 72篇 |
1986年 | 81篇 |
1985年 | 94篇 |
1984年 | 59篇 |
1983年 | 69篇 |
1982年 | 41篇 |
1981年 | 27篇 |
1980年 | 35篇 |
1979年 | 42篇 |
1978年 | 40篇 |
1977年 | 39篇 |
1976年 | 38篇 |
1975年 | 44篇 |
1974年 | 49篇 |
1973年 | 34篇 |
1972年 | 32篇 |
排序方式: 共有4526条查询结果,搜索用时 15 毫秒
1.
2.
Changes in Speckle Tracking Echocardiography Measures of Ventricular Function after Percutaneous Implantation of the Edwards SAPIEN Transcatheter Heart Valve in the Pulmonary Position 下载免费PDF全文
Shahryar M. Chowdhury M.D. Ziyad M. Hijazi M.D. John F. Rhodes M.D. Saibal Kar M.D. Raj Makkar M.D. Michael Mullen M.D. Qi‐Ling Cao M.D. Lazar Mandinov M.D. Ph.D. Jason Buckley M.D. Nicholas P. Pietris M.D. Girish S. Shirali M.B.B.S. F.A.C.C. F.A.S.E. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(3):461-469
3.
Javed Butler Mei Yang Massimiliano Alfonzo Manzi Gregory P. Hess Mahesh J. Patel Thomas Rhodes Michael M. Givertz 《Journal of the American College of Cardiology》2019,73(8):935-944
Background
Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.Objectives
The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.Methods
Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.Results
Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.Conclusions
In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy. 相似文献4.
5.
6.
Concurrent beneficial (vitamin D production) and hazardous (cutaneous DNA damage) impact of repeated low‐level summer sunlight exposures 下载免费PDF全文
7.
8.
9.
Ram N. Bishnoi Allen D. Everett Richard E. Ringel Carl Y. Owada Ralf J. Holzer Joanne L. Chisolm Wolfgang A. Radtke D. Scott Lim John F. Rhodes Jr John D. Coulson 《Pediatric cardiology》2014,35(7):1124-1131
This study aimed to assess the technical aspects of atrial septal defect (ASD) closure using the Amplatzer septal occluder (ASO) and the Gore Helex septal occluder (GHSO) for infants weighing less than 8 kg and to determine the safety, effectiveness, and near-to-intermediate-term outcome of the closure. The Mid-Atlantic Group of Interventional Cardiology Registry of percutaneous, transcatheter ASD closure procedures was reviewed for this analysis. Patients from 10 hospitals in the United States were included. The cohort for this report consisted of 68 patients weighing less than 8 kg (range, 2.3–7.8 kg; mean, 5.5 ± 1.6 kg) and ranging in age from 1 to 24 months (mean, 8.6 ± 4.7 months). The indications for ASD closure were failure to thrive, significant right heart enlargement, shunts otherwise thought to be hemodynamically significant, and poor overall clinical status. Devices were successfully implanted in 66 of the 68 infants (97.1 % procedural success rate). Five minor procedure-related complications occurred. At follow-up assessment, clinical status had improved significantly as measured by improved weight gain and decreased ventilator or oxygen dependence. All residual shunts spontaneously closed during the follow-up period. Six late deaths occurred, none of which were clearly device related. The ASO and GHSO can be safely and effectively implanted for ASD closure in infants weighing less than 8 kg. These procedures usually are successful and seldom complicated, resulting in significant clinical improvement. 相似文献
10.
Emily C. Rhodes Sahil P. Parikh Nishith Bhattacharyya 《Pediatric surgery international》2014,30(2):243-244
Autoimmune hemolytic anemia is a type of hemolytic anemia characterized by autoantibodies directed against red blood cells shortening their survival. When autoimmune hemolytic anemia is secondary to a paraneoplastic process, severe anemia can occur leading to significant morbidity and even mortality. Here we discuss the literature and present the case of a child with autoimmune hemolytic anemia from a paraneoplastic syndrome secondary to a renal tumor. 相似文献